Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States

BACKGROUND: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whether disti...

Descripción completa

Detalles Bibliográficos
Autores principales: Adegunsoye, Ayodeji, Baccile, Rachel, Best, Thomas J., Zaksas, Victoria, Zhang, Hui, Karnik, Rasika, Patel, Bhakti K., Solomonides, Anthony E., Parker, William F., Solway, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410516/
https://www.ncbi.nlm.nih.gov/pubmed/37564420
http://dx.doi.org/10.1016/j.lana.2023.100566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410516/
https://www.ncbi.nlm.nih.gov/pubmed/37564420
http://dx.doi.org/10.1016/j.lana.2023.100566

Ejemplares similares